AUS
NZ
UK
CA
USA
IND
Healt
Can FebriDx Drive Lumos Diagnostics’ US Expansion?
April 14, 2026 04:46 PM AEST| By SamLumos Diagnostics accelerates FebriDx adoption across US urgent care centres, strengthening its commercial presence and supporting faster clinical decision-making in respiratory care.
Could Jupiter Unlock a New Rare Earths Breakthrough?
April 14, 2026 04:27 PM AEST| By SamCritica’s Jupiter project shows encouraging rare earth recovery progress, with advancing studies and optimisation efforts supporting future development in Western Australia’s resource sector.
Could Psychedelic Science Redefine Binge Eating Treatment?
April 14, 2026 04:23 PM AEST| By SamA clinical update highlights advancements in psychedelic therapy for binge eating disorder, showcasing controlled treatment methods, ongoing trials, and growing interest in innovative mental health solutions.
Aroa Biosurgery Gains as All Ordinaries Sees Healthcare Growth
April 14, 2026 04:00 PM AEST| By SamAroa Biosurgery operates within the healthcare sector using ECM technology, maintaining a debt-free structure while expanding commercial activity and reducing financial losses.
Can Percheron’s Fresh Funding Drive Its Cancer Therapy Forward?
April 14, 2026 02:39 PM AEST| By SamPercheron advances its cancer therapy with fresh funding, setting up the next clinical phase while drawing attention through upcoming research presentations and strategic progress.
All Ordinaries Healthcare Stocks US Market Expansion Focus
April 14, 2026 12:10 PM AEST| By SamHealthcare sector activity highlights milestone payments and international expansion, reflecting continued commercial progress in diagnostic technology within the All Ordinaries index.
How Orthocell Limited (ASX:OCC) Fits in ASX 300 Healthcare Sector Trends
April 14, 2026 11:30 AM AEST| By SamOrthocell prepares quarterly update and investor webinar, reflecting healthcare sector activity and biotechnology development within Australian equity markets.
ASX 200 Healthcare Stock (ASX:TLX): How Telix’s Regeneron Deal and FDA Progress Are Reshaping Its Growth Narrative
April 14, 2026 10:51 AM AEST| By SamTelix Pharmaceuticals gains momentum after a Regeneron partnership and FDA milestone, strengthening its transition toward a multi-product oncology platform, though execution risks and reliance on imaging revenues remain key considerations.
Telix (ASX:TLX) Signals Fresh Growth Trajectory Amid Expanding Footprint
April 13, 2026 03:36 PM AEST| By Team Kalkine MediaTelix Pharmaceuticals advances its oncology strategy through a major collaboration and regulatory milestone, strengthening its radiopharmaceutical platform and expanding its presence beyond core imaging markets.
Is Monash IVF Near a Deal as Takeover Pressure Builds?
April 13, 2026 03:29 PM AEST| By SamMonash IVF reviews a revised takeover proposal as investor interest grows, highlighting valuation debates, sector demand trends, and strategic decisions shaping the company’s future.
Small Move, Big Signal? Syntara’s ASX Update Explained
April 13, 2026 10:53 AM AEST| By SamSyntara has applied to list new shares on the ASX, reflecting routine capital management activity that slightly expands its equity base while improving liquidity and maintaining transparency.
Breakthrough Tech Buzz: Is This ASX Small Cap Turning Heads?
April 13, 2026 10:50 AM AEST| By SamEBR Systems is gaining attention as its cardiac technology sees growing commercial use and clinical progress, highlighting its role in advancing minimally invasive healthcare solutions within the Australian market.
Aroa Biosurgery Drives Momentum Beyond ASX 200 Buzz
April 10, 2026 10:35 PM AEST| By Team Kalkine MediaAroa Biosurgery strengthens its growth pathway through new share quotation, supporting innovation, expanding market reach, and aligning with broader trends shaping Australia’s healthcare and equity environment.
Is Sonic Healthcare Facing a Valuation Reset at Lows?
April 10, 2026 06:43 PM AEST| By SamSonic Healthcare’s valuation debate deepens as shares hover near long-term lows, with investors weighing sector challenges against evolving healthcare demand and future growth drivers.
Healthcare Momentum Builds as ASX 200 Focus Turns to Strength
April 10, 2026 04:45 PM AEST| By Team Kalkine MediaA healthcare stock on the ASX gains attention as broader markets face pressure, highlighting sector resilience, operational developments, and investor focus shifts.
Telix Pharmaceuticals ASX 200 FDA Drug Progress Focus
April 10, 2026 04:21 PM AEST| By SamTelix Pharmaceuticals progresses regulatory review for its imaging drug, reflecting continued activity within the healthcare and biotechnology sector in Australia.
Arovella ASX Developments Reflect Activity With Healthcare Segment
April 10, 2026 03:46 PM AEST| By SamArovella Therapeutics advances share quotation, reflecting continued activity within the biotech sector and structured participation in the ASX stock market.
ASX 200 Healthcare Stocks: Is Value Emerging After Sell-Off?
April 10, 2026 11:06 AM AEST| By SamASX healthcare stocks face pressure, but emerging value opportunities and companies like Telix highlight long-term growth potential within the ASX 200 sector.
ASX Biotech Stock CHM Crashes: Panic or Opportunity?
April 10, 2026 10:39 AM AEST| By SamChimeric Therapeutics faces sharp decline amid heavy selling, highlighting volatility in ASX biotech small-cap stocks and broader sector pressure.
ASX Healthcare Stock CGS Adds Shares in Quiet Move
April 10, 2026 10:09 AM AEST| By SamCogstate lists additional shares on the ASX following securities conversion, reflecting routine capital management within the healthcare technology sector.
Advertise your brand on Kalkine Media